Suberohydroxamic acid phenyl ester: Phase Ib data

A double-blind, placebo-controlled, U.S. Phase Ib trial in 18 patients with stage Ia-IIa CTCL showed that twice-daily 0.1%, 0.5% and 1% topical SHAPE for 28 days led to 4 objective responses defined as a >50% improvement in lesion severity as measured by CAILS (n=15). Additionally, 6 patients receiving SHAPE had weekly incremental CAILS improvements over 28 days. No dose-limiting toxicities (DLTs) or serious adverse events were reported. Data were presented at the Society for Investigative Dermatology meeting in Albuquerque. ...